Phase 4 Completed N=89 Randomized Quadruple-blind Prevention

Probiotics to Promote Intestinal Health

Communicable Diseases · Infections · Anti-Infective Agents · Therapeutic Uses

Source: ClinicalTrials.gov NCT02046512 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2022

Primary outcomePrimary: Number of Participants With Acquisition of Any New Antibiotic-resistant Organism — 9; 12 Participants

◆ Published Evidence

No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The purpose of this study is to evaluate the effectiveness of bacteria called Lactobacillus GG, a Probiotic, in preventing the growth of resistant bacteria in the digestive tract in patients on broad spectrum antimicrobials.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Acquisition of Any New Antibiotic-resistant Organism	9; 12	—

Eligibility Criteria

Inclusion Criteria

Adults ≥ 18 years old
Admission to the non-ICU medical and surgical wards
On broad spectrum antimicrobials with an anticipated length of stay of >48 hours

Exclusion Criteria

Pregnancy
Non English speaking
Expected to die within 7 days
Unable or unwilling to consent
HIV infection with a CD4 count <200
Neutropenia with an absolute neutrophil count less than 500 cells/ml (or expected to drop to less than 500)
Clinically significant diarrhea or history of C. difficile infection in the last 3 months
History of VRE colonization and/or infection in the last year
Transplant recipients

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02046512). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.